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Text
Missense mutations in breast cancer predisposition
genes are a substantial clinical problem. These are usu-
ally considered variants of uncertain significance (VUS)
until genetic, clinical, and functional data provide statis-
tical evidence for reclassification as pathogenic or
neutral.
Recently, Park et al. [1] suggested that the WD40
domain of the protein encoded by the breast cancer
predisposition gene PALB2 may scaffold RAD51C,
RAD51, and BRCA2 proteins into a complex involved
in DNA repair mediated by homologous recombin-
ation (HR). The authors studied the effect of
p.Leu939Trp and other missense mutations located
within the PALB2 WD40 domain that had been iden-
tified in the germline of women with breast cancer.
They reported that the p.Leu939Trp mutation re-
sulted in altered PALB2–BRCA2 binding, decreased
capacity for DNA double-strand break-induced HR,
and increased sensitivity to ionizing radiation. Based
on these observations and their assertion that this
mutation occurs more frequently in women with
breast cancer than in unaffected women, Park et al.
[1] concluded that the p.Leu939Trp mutation may be
pathogenic and proposed that their assays could be
used for the functional characterization of other
PALB2 missense variants.
Case-control, rather than case-only studies are re-
quired to estimate the relative risk associated with a
genetic variant. Park et al. refer to p.Leu939Trp as a
breast cancer-associated mutation; however, among
the studies they cited to sustain this hypothesis, only
one was a case-control study [2]. Further, case-control
data from Rahman et al. [3] were not considered,
even though this study is referenced in their report.
These two studies [2, 3] together identified the
p.Leu939Trp mutation in 10/1741 (0.57 %) women
with breast cancer and 8/1534 (0.52 %) unaffected
controls, suggesting that this mutation is not associ-
ated with breast cancer risk. Further, we later pub-
lished a third study corroborating this null finding [4]
and have subsequently reported additional evidence
that the p.Leu939Trp mutation is not associated with
breast cancer risk, based on genotyping of 42,671
breast cancer cases and 42,164 controls (odds ratio = 1.05,
95 % confidence interval = 0.83–1.32, p value = 0.70) [5].
Finally, we observed that the p.Leu939Trp mutation does
not disrupt the HR-mediated DNA repair activity of
PALB2 (Fig. 1).
Results from functional assays with undefined sensitiv-
ity and specificity are not sufficient to classify VUS. In
this instance, the p.Leu939Trp mutation may have some
influence on response to ionizing radiation but it ap-
pears to have little to no impact on HR-mediated DNA
repair. In conclusion, our findings suggest that the
PALB2 p.Leu939Trp mutation should be classified as a
neutral variant with no clinical relevance to risk of
breast cancer.
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Fig. 1 Homologous recombination assay for the p.Leu939Trp
mutation. B400 palb2−/−; tp53−/− mouse mammary tumor cells were
co-transfected with direct repeat-green fluorescent protein (DR-GFP)
reporter and recombinant constructs expressing normal (used as
positive control), p.Tyr551* (used as negative control) and p.Leu939Trp
mutated PALB2 alleles. The error bars represent the Standard Error (SE)
of the mean from three independent experiments. GFP-positive cells
were assessed by flow cytometry. Comparable expression level of
normal and p.Leu939Trp mutated PALB2 proteins was observed by
western blot (data not shown)
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